Terminal respiratory unit type lung adenocarcinoma is associated with distinctive EGFR immunoreactivity and EGFR mutations.

摘要: Approximately 10% to 20% of nonsmall cell lung cancer patients respond epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib. Responders are mostly nonsmokers and women with tumors displaying bronchioloalveolar features. Mutations the domain EGFR gene have been associated a clinical response A recent study reported that terminal respiratory unit (TRU)-type adenocarcinoma shares profile mutations gefitinib responders. immunoreactivity in this context has not literature. We performed detailed immunohistochemical analysis expression on 124 consecutive resection specimens for malignancy, survey cancers general correlate TRU-type histology. positivity was seen most frequently squamous carcinomas (77%), followed by adenocarcinomas (63%), large (23%), non-TRU-type (12%). distinctive basally oriented cytoplasmic observed exclusively adenocarcinomas. mutation identified 6 54 cases studied all were Five six positive immunostain basal localization. In conclusion, pattern subset these responders inhibitor therapy.